<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Lankanau Institute For Medical Research</title><link href="http://howtoavoidaheartattack.com/topic/lankanau-institute-for-medical-research" rel="alternate"></link><id>http://howtoavoidaheartattack.com/topic/lankanau-institute-for-medical-research</id><updated>2010-03-15T08:15:53Z</updated><entry><title>Experimental blood-thinner effective: study</title><link href="http://howtoavoidaheartattack.com/cardiovascular-medicine/experimental-bloodthinner-effective-study-874331a" rel="alternate"></link><updated>2010-03-15T08:15:53Z</updated><author><name>AFP Global Edition</name></author><id>tag:howtoavoidaheartattack.com,2010-03-15:/cardiovascular-medicine/experimental-bloodthinner-effective-study-874331a/</id><summary type="html">&lt;div&gt;&lt;p&gt;An experimental blood thinner developed by Merck and &lt;a title="Portola Pharmaceuticals Inc." href="/topic/Portola+Pharmaceuticals+Inc." &gt;Portola Pharmaceuticals&lt;/a&gt; was found to be safe and effective in a mid-stage study presented Monday, with a lower incidence of serious bleeding than current drugs.&lt;/p&gt;&lt;p&gt;The Phase II randomized trial compared the effects of betrixaban, which is part of a new class of drugs, to the widely used warfarin in 508 patients in the &lt;a title="United States" hre...</summary><category term="Clinical Trials"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Germany"></category><category term="Philadelphia"></category><category term="Europe"></category><category term="Atlanta"></category><category term="Canada"></category><category term="Pennsylvania"></category><category term="Western Europe"></category><category term="American College of Cardiology"></category><category term="Cardiovascular Medicine"></category><category term="Portola Pharmaceuticals Inc."></category><category term="Michael Ezekowitz"></category><category term="Lankanau Institute for Medical Research"></category></entry><entry><title>Experimental Merck blood-thinner found effective</title><link href="http://howtoavoidaheartattack.com/cardiovascular-medicine/experimental-merck-bloodthinner-effective-874264a" rel="alternate"></link><updated>2010-03-15T07:16:02Z</updated><author><name>AFP American Edition</name></author><id>tag:howtoavoidaheartattack.com,2010-03-15:/cardiovascular-medicine/experimental-merck-bloodthinner-effective-874264a/</id><summary type="html">&lt;div&gt;&lt;p&gt;An experimental blood thinner developed by Merck and &lt;a title="Portola Pharmaceuticals Inc." href="/topic/Portola+Pharmaceuticals+Inc." &gt;Portola Pharmaceuticals&lt;/a&gt; was found to be safe and effective in a mid-stage study presented Monday, with a lower incidence of serious bleeding than current drugs.&lt;/p&gt;&lt;p&gt;The Phase II randomized trial compared the effects of betrixaban, which is part of a new class of drugs, to the widely used warfarin in 508 patients in the &lt;a title="United States" hre...</summary><category term="Clinical Trials"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Germany"></category><category term="Philadelphia"></category><category term="Europe"></category><category term="Atlanta"></category><category term="Canada"></category><category term="Pennsylvania"></category><category term="Western Europe"></category><category term="American College of Cardiology"></category><category term="Cardiovascular Medicine"></category><category term="Portola Pharmaceuticals Inc."></category><category term="Michael Ezekowitz"></category><category term="Lankanau Institute for Medical Research"></category></entry></feed>
